Cetuximab for Squamous Cell Carcinoma of the Head and Neck

Larizadeh, Mohammad Hasan

doi:10.5812/ijcm.10502

Cited by 2 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cetuximab has been investigated both in the induction phase and concomitant phase (bioradiation) of non-surgical approaches. 8,9 To the best of our knowledge, the results of non-surgical treatment in hypopharyngeal cancer are rarely reported. No study has been conducted on hypopharyngeal cancer in the southeast of Iran.…”

Section: Introductionmentioning

confidence: 99%

The Patients’ Characteristics and Non-Surgical Treatment Results for Hypopharyngeal Cancer in Southeast of Iran: A 13-Year Study

Larizadeh

Mianroodi

Eslami

2023

J Ayub Med Coll Abbottabad

View full text Add to dashboard Cite

Background: Various modalities have been used to treat hypopharyngeal cancer. Non- surgical modalities include radiotherapy alone, sequential chemoradiation and concomitant chemoradiation or bio radiation. This study was conducted to evaluate the primary non-surgical treatment. Methods: A total number of 67 patients treated from March 2009 to January 2022 were enrolled in this study. The 2-year and 5-year survival rates were estimated using the Kaplan-Meier method. Log-rank test was used to compare the survival outcomes according to various factors. To define independent prognostic factors, we used Cox regression analysis. Results: The mean age of the patients was 56.2 years, and 55.2% of them were male. These patients were treated by radiation alone (9 patients) or induction chemotherapy followed by either radiation (4 patients), chemoradiation (33 patients), or bio-radiation (21 patients). The mean follow-up time was 18.12 months. The 2-year and 5-year overall survival rates were estimated to be 43% and 18%, respectively. Multivariate analysis showed that T stage, N stage, and treatment modality had a statically significant relationship with overall survival. Conclusion: The results of non-surgical treatment for hypopharyngeal cancer are not satisfactory. More studies are needed to investigate the role of salvage surgery.

show abstract

Section: Introductionmentioning

confidence: 99%

The Patients’ Characteristics and Non-Surgical Treatment Results for Hypopharyngeal Cancer in Southeast of Iran: A 13-Year Study

Larizadeh

Mianroodi

Eslami

2023

J Ayub Med Coll Abbottabad

View full text Add to dashboard Cite

show abstract

Induction Chemotherapy Followed by either Chemoradiotherapy or Bioradiotherapy in Laryngeal Cancer

Larizadeh

Mohammadi

Shabani

et al. 2021

Asian Pac J Cancer Prev

Self Cite

View full text Add to dashboard Cite

Objective: In loco regionally advanced head and neck cancer, the superiority of concomitant cetuximab with radiation over radiation alone has been proven previously. But comparison between chemo radiation and bioradiation has not been well studied. Methods: Between October 2013 and August 2017, 38 patients with locoregionally advanced laryngeal cancer and more than 50% response to 3 cycles of induction chemotherapy (docetaxel and cisplatin: both with a dose of 75 mg/m 2 on the first day and 5-flurouracil: 750 mg/m 2 during days 1to 3; repeated every 21 days) were selected to receive either carboplatin (18 patients, AUC 1.5 , weekly) or cetuximab (20 patients, with loading dose of 400 mg/m 2 and weekly dose of 250 mg/m2) with radiation. A Kaplan–Meier analysis was used to calculate progression free survival and overall survival rates. The log–rank test was used to compare overall survival between treatment groups. Results: The median follow up time was 36 months. The 2-year organ preservation rate of 78.9% was achieved. The 3- year progression-free survival rates of 65.2%, 72.7% and 58.2% were observed for all patients, carboplatin group and cetuximab group, respectively (p=0.4). The 3-year estimates of overall survival were 67.8%, 69.2 %, and 66.3 % for all patients, carboplatin group and cetuximab group, respectively (p=0.47). Concomitant carboplatin was discontinued in 3 patients due to toxicity Conclusion: Concomitant cetuximab is a reasonable alternative to concomitant chemotherapy. But the difference in treatment outcome between bioradiation and chemoradiation remains to be defined.

show abstract

Cetuximab for Squamous Cell Carcinoma of the Head and Neck

Cited by 2 publications

References 37 publications

The Patients’ Characteristics and Non-Surgical Treatment Results for Hypopharyngeal Cancer in Southeast of Iran: A 13-Year Study

The Patients’ Characteristics and Non-Surgical Treatment Results for Hypopharyngeal Cancer in Southeast of Iran: A 13-Year Study

Induction Chemotherapy Followed by either Chemoradiotherapy or Bioradiotherapy in Laryngeal Cancer

Contact Info

Product

Resources

About